LONDON, UK, Monday 29 June 2015, 07:00 GMT+1 – Norgine B.V. presents new data highlighting a perceptual gap between healthcare professionals and patients in terms of the incidence and impact on patients’ daily life of chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV).
These data were sponsored by Norgine and presented at the joint Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO) 2015 Annual Meeting.
The data demonstrate that physicians and oncology nurses overestimate the incidence of CINV/RINV, but underestimate the impact of the condition on patients’ daily lives (p<0.05). These findings were echoed by 28% of patients who feel oncologists underestimate the impact of CINV/RINV. In addition, the incidence of nausea was shown to be greater than vomiting, with 60% of patients reporting nausea alone, compared to just 4% for vomiting and 14% for nausea and vomiting (NV). Acceptance of NV as an inevitable consequence of chemo and radiotherapy can prevent patients reporting to the healthcare professionals, in turn preventing its active management. 1
In addition, just 38% of patients reported full compliance with physicians’/nurses’ guidelines when self-administering anti-emetic medication, compared with 60% estimated by physicians and nurses. Leading factors given for poor patient compliance included reluctance to add to a pill burden and fear that swallowing itself would induce nausea/vomiting.1
Nausea and vomiting is estimated to affect 35-50% of patients undergoing chemotherapy and/or radiotherapy2, and previous studies have shown that treatment-induced NV has a significant impact on the quality of life in up to 40% of patients.3
Donna McVey, Chief Development Officer Norgine, commented, “The disconnect may lead to sub-optimal prescribing and therefore inadequate management of CINV/RINV and so needs to be addressed by healthcare professionals to ensure effective treatment. In addition, for some patients, it is important to reduce the pill burden and the use of orodispersible film delivery systems can improve patient compliance.”
NOTES TO EDITORS
About the oral abstract presented at MASCC/ISOO 2015
Impact and management of chemotherapy / radiotherapy induced nausea and vomiting and then perceptual gap between oncologists, oncology nurses and patients: a multinational cross-sectional study1
The study aimed to investigate the incidence and impact that chemotherapy- and radiotherapy-induced nausea and vomiting (CINV and RINV) has on patients’ quality of life versus estimations by oncology physicians and nurses to determine if there is a perceptual gap between healthcare professionals and patients. An online research survey of oncologists, oncology nurses and patients was conducted across five European countries. Participants had experience of prescribing/recommending or having received anti-emetics for CINV/RINV treatment. The data showed the incidence of nausea was greater than vomiting with 60% of patients reporting nausea alone whereas 18% reported vomiting. Physicians/nurses overestimated the incidence of CINV/RINV, but underestimated the impact that this had on patients’ daily lives. The results showed there is a perceptual gap between healthcare professionals and patients in terms of incidence and impact of CINV/RINV and this may lead to sub-optimal prescription and therefore management of.
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine’s total revenue was €296 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Isabelle Jouin, T: +44 (0)1895 453643
Charlotte Andrews, T: +44 (0)1895 453607
Follow us @norgine
 Vidall C. et al. Impact and management of chemotherapy / radiotherapy induced nausea and vomiting and the perceptual gap between oncologists, oncology nurses and patients: a multinational cross-sectional study. Support Care Cancer 2015; 23(1):S125
 Grunberg S. et al. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting. Support Care Cancer 2010; 18(1):S1-10
 Lindley CM. et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992; 1:331-340